ReviewFrontiers in microbiology2016
Phage Therapy: Combating Infections with Potential for Evolving from Merely a Treatment for Complications to Targeting Diseases.
Review in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
80 citing papers in PubMed, 147 citations in OpenAlex.
- From Gut to Reproductive Health: Exploring Microbiome Interactions and Future Interventions.Reproductive sciences (Thousand Oaks, Calif.) · 2025Review
- Characterizing Gut Microbiota Composition and Its Correlation with Growth Variation in Sea Cucumber Apostichopus japonicus.Marine biotechnology (New York, N.Y.) · 2025Article
- Fighting biofilm: bacteriophages eliminate biofilm formed by multidrug-resistant Enterobacter hormaechei on urological catheters.Medical microbiology and immunology · 2025Article
- Phage and Endolysin Therapy Against Antibiotics Resistant Bacteria: From Bench to Bedside.MedComm · 2025Review
- Phage therapeutic delivery methods and clinical trials for combating clinically relevant pathogens.Therapeutic delivery · 2025Review
- A Comprehensive Review on Phage Therapy and Phage-Based Drug Development.Antibiotics (Basel, Switzerland) · 2024Review
- Phage Therapy: An Alternative Approach to Combating Multidrug-Resistant Bacterial Infections in Cystic Fibrosis.International journal of molecular sciences · 2024Review
- Does Phage Therapy Need a Pan-Phage?Pathogens (Basel, Switzerland) · 2024Review
- Characterization and complete genome analysis of Klebsiella phage Kp109 with lytic activity against Klebsiella pneumoniae.Virus genes · 2024Article
- Microbiome Dynamics: A Paradigm Shift in Combatting Infectious Diseases.Journal of personalized medicine · 2024Review
- The applications of animal models in phage therapy: An update.Human vaccines & immunotherapeutics · 2023Review
- Phage Therapy, a Salvage Treatment for Multidrug-Resistant Bacteria Causing Infective Endocarditis.Biomedicines · 2023Review
- Isolation and Characterization of theMicroorganisms · 2023Article
- Bacteriophage Therapy as an Application for Bacterial Infection in China.Antibiotics (Basel, Switzerland) · 2023Review
- Attenuation of quorum sensing system and virulence inFrontiers in microbiology · 2023Article
- Characterization of anFrontiers in microbiology · 2023Article
- Modification of the immune response by bacteriophages alters methicillin-resistant Staphylococcus aureus infection.Scientific reports · 2022Article
- Fecal Microbiota Transplantation as New Therapeutic Avenue for Human Diseases.Journal of clinical medicine · 2022Review
- Isolation of a lytic bacteriophage against extensively drug-resistant Acinetobacter baumannii infections and its dramatic effect in rat model of burn infection.Journal of clinical laboratory analysis · 2022Article
- Construction and Characterization of T7 Bacteriophages Harboring Apidaecin-Derived Sequences.Current issues in molecular biology · 2022Article
20 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance is considered to be one of the greatest challenges of medicine and our civilization. Lack of progress in developing new anti-bacterial agents has greatly revived interest in using phage therapy to combat antibiotic-resistant infections. Although a number of clinical trials are underway and more are planned, the realistic perspective of registration of phage preparations and their entering the health market and significantly contributing to the current antimicrobial crisis is rather remote. Therefore, in addition to planning further clinical trials, our present approach of phage treatment carried out as experimental therapy (compassionate use) should be expanded to address the growing and urgent needs of increasing cohorts of patients for whom no alternative treatment is currently available. During the past 11 years of our phage therapy center's operation, we have obtained relevant clinical and laboratory data which not only confirm the safety of the therapy but also provide important information shedding more light on many aspects of the therapy, contributing to its optimization and allowing for construction of the most appropriate clinical trials. New data on phage biology and interactions with the immune system suggest that in the future phage therapy may evolve from dealing with complications to targeting diseases. However, further studies are necessary to confirm this promising trend.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.